Annexure IX - Statement of Assets & Liabilities

(o) Cash and cash equivalents

(p) Short-term loans and advances

B2. Sub-total - Current assets (m+u+o+p+q)

(q) Other current assets

Financial Results for Quarter ended 31st March, 2013 (₹ in lac unless otherwise stated)

	Quarter Ended			Year Ended	
Particulars	Mar 2013 Dec 2012		Mar 2012	Mar 2013	Mar 2012
	Audited*	Unaudited	Audited*	Audited	Audited
(a) Net sales/income from operations	1796.77	1168.55	1425.49	5430.89	5391.5
(b) Other operating income	109.07	33.28	43.68	179.96	121.4
l. Total income from operations (net) (a+b)	1905.83	1201.83	1469.17	5610.85	5512.9
(c) Cost of materials consumed	977.16	863.95	1134.60	3619.30	3721.2
(d) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	285.0
(e) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	240.04	-151.18	-82.61	17.85	2.5
(f) Employee benefits expense	180.48	180.22	133.16	605.27	453.6
(g) Depreciation and amortization expense	231.74	195.49	25.69	472.85	100.3
(h) Other expenses	375.02	243.79	210.56	1069.35	793.5
2. Total expenses (c+d+e+f+g+h)	2004.45	1332.27	1421.40	5784.62	5356.2
3. Profit/ Loss(-) from operations before other income and finance costs (1-2)	-98.61	-130.44	47.77	-173.77	156.7
4. Other income	-1.20	15.88	0.94	46.98	54.0
5. Profit/ Loss(-) from ordinary activities before finance costs (3+4)	-99.81	-114.55	48.71	-126.79	210.7
5. Finance costs	52.26	66.85	32.55	194.46	127.2
7. Profit/ Loss(-) from ordinary activities before tax (5-6)	-152.07	-181.41	16.16	-321.25	83.5
3. Tax expense	107.79		30.56	115.54	30.7
P. Net Profit/ Loss(-) from ordinary activities after tax (9-10)	-259.85	-181.41	-14.40	-436.80	52.8
J. Paid-up equity share capital (Face Value ₹ 10 Each)	2104.06	2104.06	2104.06	2104.06	2104.0
11. Reserves excluding Revaluation Reserves as per bal. sheet of prev.	in the same			7678.79	7625.9
2ªBasic and Diluted Earnings per share in ₹ (not annualized)	-1.23	-0.86	-0.07	-2.08	0.2
A1. Public shareholding - Number of shares	10319030	10319030	10319030	10319030	1031903
- Percentage of shareholding	49.04%	49.04%	49.04%	49.04%	49.049
42. a) Promoters and Promoter Group Pledged/ Encumbered No. of shares	О	0	0	. 0	
- Percentage of total shareholding of promoters & promoter group	0.00%	0.00%	0.00%	0.00%	0.009
- Percentage of total share capital of the company	0.00%	0.00%	0.00%	0.00%	0.009
A2. b) Promoters and Promoter Group Non-encumbered No. of shares	10721570	10721570	10721570	10721570	1072157
- Percentage of total shareholding of promoters & promoter group	100.00%	100.00%	100.00%	100.00%	100.009
- Percentage of total share capital of the company	50.96%	50.96%	50.96%	50.96%	50.96%
B. Investor Complaints: Pending at the start of the qtr.	0	Received during the qtr.			- 1
Disposed off during the qtr.	1	Unresolved till end of the qtr. 0			

lac unless otherwise stated)

Particulars	Mar 2013	Mar 2012	Board Audit Co	
	Audited	Audited	approved by the	
(a) Share capital	2104.06	2104,06	meeting today	
(b) Reserves and surplus	7241.99	7678.79		
A1. Sub-total - Shareholders' funds (a+b)	9346.05	9782.85	2. The Company segment of Drug	
(c) Long-term borrowings	620.10	266.67		
(d) Deferred tax liabilities (net)	137.88	22.34		
(e) Other long-term liabilities	100.07	71.74	3. The Provision	
A2. Sub-total - Non-current liabilities (c+d+e)	858.05	360.74	been made for t	
(f) Short-term borrowings	804.18	784.59	periods.	
(g) Trade payables	851.53	1554.85		
(h) Other current liabilities	540.47	436.49	4. The Figures of may have been	
(i) Short-term provisions	56.23	81.24		
A3. Sub-total - Current liabilities (f+g+h+i)	2252.41	2857.17	wherever neces	
TOTAL - EQUITY AND LIABILITIES (A1+A2+A3)	12456.50	13000.76		
(j) Fixed assets	7998.61	920.92	5 *The Govern	
(k) Capital work-in-progress	0.00	6426.07	5. *The figures of balancing figure in respect of the	
(I) Long-term loans and advances	85.28	82.07		
B1. Sub-total - Non-current assets (j+k+l)	8083.88	7429.05	the published ye	
(m) Inventories	1330.18	1554.16	the third quarter	
(n) Trade receivables	1947.04	2141.43		

TOTAL - ASSETS (B1+B2)

- 1. The results have been reviewed by Board Audit Committee and have been approved by the Board of Directors at its
- 2. The Company is operating in the single segment of Drugs & Chemicals.
- 3. The Provision for Tax may not have been made for the partial/ unaudited periods.
- 4. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- 5. *The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of that financial year.

For ALPA LABORATORIES LIMITED
M. S. Chawla, Director

5571.71 Place: Pigdamber, Rau, Indore 13000.76 Date: 30th May, 2013

14.94

549.05

1312.13

52.73

987.82

54.84

4372.62

12456.50